Wai Chun Bio-Technology Limited Announces Poll Results of Extraordinary General Meeting

Key Highlights for Investors

• Extraordinary General Meeting (EGM) Held: The EGM took place on 24 April 2026, as announced by Wai Chun Bio-Technology Limited.
• Resolution Passed: The only resolution proposed at the meeting, relating to the approval, confirmation, authorization, and ratification of the Loan Agreement and its associated Drawdowns, was unanimously passed with 100% of votes in favour and 0% against.
• Shareholder Participation: Out of the total 178,476,453 issued shares, 129,789,160 shares were represented and voted at the meeting, indicating robust shareholder engagement.
• Board Attendance: All directors attended the EGM, either in person or via electronic means, signaling strong governance and oversight.
• No Restrictions or Abstentions: There were no shares requiring holders to abstain from voting, and no shareholders were mandated to abstain under the Listing Rules. No votes were cast against the resolution.
• No Treasury Shares: The company confirmed there were no treasury shares or repurchased shares pending cancellation, ensuring the voting results accurately reflect the issued share base.
• Board Composition:
  • Executive Director: Mr. Lam Ka Chun (Chairman and Chief Executive Officer)
  • Independent Non-executive Directors: Mr. Wong Po Keung, Mr. Wang Ziniu, Ms. Xu Huiling

Potential Share Price Sensitivity

The passage of the resolution concerning the Loan Agreement and related Drawdowns is potentially significant for shareholders and investors. Approval of such financial arrangements may:

• Strengthen the company’s liquidity position and financial flexibility.
• Enable Wai Chun Bio-Technology Limited to fund new projects or operations, possibly supporting future growth.
• Reflect strong shareholder support and confidence in the management’s strategic direction.

Since no shareholders abstained or voted against the resolution, and there were no treasury shares affecting the outcome, the results indicate broad consensus, which may positively influence investor sentiment. The all-in support for the Loan Agreement could be interpreted as a vote of confidence in the company’s financing strategy, potentially leading to movement in the share price, especially if the proceeds from the loan are deployed effectively.

Important Points for Shareholders

• The Loan Agreement and Drawdowns, as detailed in the circular dated 31 March 2026, are now fully authorized and ratified. Shareholders should monitor subsequent announcements for specifics on how these funds will be deployed.
• The EGM outcome reflects strong governance, with all directors present and participating.
• No adverse shareholder actions or regulatory restrictions were reported, suggesting a stable corporate environment.

Conclusion

The outcome of Wai Chun Bio-Technology Limited’s EGM demonstrates high shareholder engagement and confidence in the company’s financial strategy. The approval of the Loan Agreement may enhance operational capabilities and support future initiatives. Investors should remain alert for follow-up disclosures regarding the use of loan proceeds, which may have direct implications for the company’s performance and share value.

Disclaimer: This article is provided for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making any investment decisions. The author and publisher bear no responsibility for any losses arising from reliance on the information contained herein.

View WAI CHUN BIOTEC Historical chart here